Machine learning assisted methods for the identification of low toxicity inhibitors of Enoyl-Acyl Carrier Protein Reductase (InhA)

被引:2
|
作者
Chikhale, Rupesh, V [1 ]
Abdelghani, Heba Taha M. [2 ]
Deka, Hemchandra [3 ]
Pawar, Atul Darasing [3 ]
Patil, Pritee Chunarkar [4 ]
Bhowmick, Shovonlal [3 ]
机构
[1] UCL, Sch Pharm, Dept Pharmaceut & Biol Chem, London, England
[2] King Saud Univ, Coll Sport Sci & Phys Act, Dept Exercise Physiol, Riyadh 11451, Saudi Arabia
[3] SilicoScientia Pvt Ltd, Nagananda Commercial Complex 07-3,15-1,18th Main R, Bengaluru 560041, India
[4] Bharati Vidyapeeth Deemed Univ, Rajiv Gandhi Inst IT & Biotechnol, Dept Bioinformat, Pune Satara Rd, Pune, India
关键词
Tuberculosis; Enoyl-Acyl Carrier Protein Reductase; Molecular docking; Machine learning; Molecular dynamics simulation; MYCOBACTERIUM-TUBERCULOSIS; ISONIAZID ANALOG; GROMACS;
D O I
10.1016/j.compbiolchem.2024.108034
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tuberculosis (TB) is one of the life-threatening infectious diseases with prehistoric origins and occurs in almost all habitable parts of the world. TB mainly affects the lungs, and its etiological agent is Mycobacterium tuberculosis (Mtb). In 2022, more than 10 million people were infected worldwide, and 1.3 million were children. The current study considered the in-silico and machine learning (ML) approaches to explore the potential anti-TB molecules from the SelleckChem database against Enoyl-Acyl Carrier Protein Reductase (InhA). Initially, the entire database of similar to 119000 molecules was sorted out through drug-likeness. Further, the molecular docking study was conducted to reduce the chemical space. The standard TB drug molecule's binding energy was considered a threshold, and molecules found with lower affinity were removed for further analyses. Finally, the molecules were checked for the pharmacokinetic and toxicity studies, and compounds found to have acceptable pharmacokinetic parameters and were non-toxic were considered as final promising molecules for InhA. The above approach further evaluated five molecules for ML-based toxicity and synthetic accessibility assessment. Not a single molecule was found toxic and each of them was revealed as easy to synthesise. The complex between InhA and proposed and standard molecules was considered for molecular dynamics simulation. Several statistical parameters showed the stability between InhA and the proposed molecule. The high binding affinity was also found for each of the molecules towards InhA using the MM-GBSA approach. Hence, the above approaches and findings exposed the potentiality of the proposed molecules against InhA.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Modification of Triclosan Scaffold in Search of Improved Inhibitors for Enoyl-Acyl Carrier Protein (ACP) Reductase in Toxoplasma gondii
    Stec, Jozef
    Fomovska, Alina
    Afanador, Gustavo A.
    Muench, Stephen P.
    Zhou, Ying
    Lai, Bo-Shiun
    El Bissati, Kamal
    Hickman, Mark R.
    Lee, Patty J.
    Leed, Susan E.
    Auschwitz, Jennifer M.
    Sommervile, Caroline
    Woods, Stuart
    Roberts, Craig W.
    Rice, David
    Prigge, Sean T.
    McLeod, Rima
    Kozikowski, Alan P.
    CHEMMEDCHEM, 2013, 8 (07) : 1138 - 1160
  • [32] Dimeric and tetrameric forms of enoyl-acyl carrier protein reductase from Bacillus cereus
    Kim, Su Jin
    Ha, Byung Hak
    Kim, Kook-Han
    Hong, Seung Kon
    Shin, Key-Jung
    Suh, Se Won
    Kim, Eunice EunKyeong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 400 (04) : 517 - 522
  • [33] Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) Antibiotics
    Yao, Jiangwei
    Rock, Charles O.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2016, 6 (03):
  • [34] Biochemical and Structural Basis of Triclosan Resistance in a Novel Enoyl-Acyl Carrier Protein Reductase
    Khan, Raees
    Zeb, Amir
    Roy, Nazish
    Magar, Roniya Thapa
    Kim, Hyo Jeong
    Lee, Keun Woo
    Lee, Seon-Woo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (08)
  • [35] Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase
    Massengo-Tiasse, R. Prisca
    Cronan, John E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (03) : 1308 - 1316
  • [36] Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase
    Xu, Jian-Fei
    Wang, Tian-Tian
    Yuan, Qing
    Duan, Yong-Tao
    Xu, Yun-Jie
    Lv, Peng-Cheng
    Wang, Xiao-Ming
    Yang, Yu-Shun
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (08) : 1509 - 1516
  • [37] Design, Synthesis and Molecular Docking of Novel Acetophenone-1,2,3-Triazoles Containing Compounds as Potent Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors
    Albelwi, Fawzia Faleh
    Mansour, Hanaa M. Abdu
    Elshatanofy, Maram M.
    El Kilany, Yeldez
    Kandeel, Kamal
    Elwakil, Bassma H.
    Hagar, Mohamed
    Aouad, Mohamed Reda
    El Ashry, El Sayed H.
    Rezki, Nadjet
    El Sawy, Maged A.
    PHARMACEUTICALS, 2022, 15 (07)
  • [38] Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis
    Khalifa, Abdalrahman
    Khalil, Amira
    Abdel-Aziz, Marwa M.
    Albohy, Amgad
    Mohamady, Samy
    BIOORGANIC CHEMISTRY, 2023, 138
  • [39] Quinazolin-4-one Derivatives: Enoyl-acyl Carrier Protein (ACP) Reductase (InhA) Antagonists Using in silico Drug Design Approach
    Kavitha, K.
    Mohan, S.
    Jothikanth., V
    Srinivasan, N.
    Manojkumar, S.
    Esakiprasanth., R.
    Jessila, Bakitha M.
    Revathi, P.
    Venkatesh, V.
    Subash, M.
    INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2024, 58 (01) : S93 - S102
  • [40] Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery
    Prasad, Mayuri S.
    Bhole, Ritesh P.
    Khedekar, Pramod B.
    Chikhale, Rupesh, V
    BIOORGANIC CHEMISTRY, 2021, 115